Over the past three decades, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) established renin-angiotensin-aldosterone system (RAAS) blockade as the cornerstone of DKD management [7,8]
Various interventions, including experimental compounds and clinically used drugs (Table 1), have shown promise in inducing ferroptosis for cancer therapy, even overcoming resistance to traditional treatments [20]
Cells continuously treated with Peg-rhArgI for 48 h showed no evidence of cytotoxicity or loss of cell viability, but were able to potently inhibit HSV-1 and HSV-2 viral replication, cell-to-cell spread/transmission, production of mature and infectious virus, and virus-mediated cytopathic effects
In hindsight we may have got good results because of a very slight (and accidental!) tweak in how we used it, but one that had big ramifications
Testing drugs like NitroSynapsin on these organoids showed promise in reducing hyperexcitability, hinting at potential treatments targeting neural imbalance